Specialised Therapeutics Asia will partner with CTTQ-Akeso to commercialise a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia.
- Welcome to Specialised Therapeutics
-
SE Asia (HQ)
+65 3158 9910
-
Australia
1300 798 820
-
New Zealand
+64 9801 0299
Partnering - Specialised Therapeutics
April 12, 2023
March 15, 2023
Thailand Office Opened
Specialised Therapeutics is thrilled to announce the official opening of its Thailand office, as we continue our mission to provide specialist therapies to patients across South East Asia. We are determined to ensure our medicines reach as many eligible patients as possible – particularly in oncology, with almost 200,000 Thai residents diagnosed with cancer every year (*Globocan 2020).
October 22, 2021
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies
Singapore, 22 October 2021: Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®). Under the
November 6, 2020
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
Singapore, 06 November 2020: A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement. Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an agreement with US-based Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialise the
December 18, 2019
Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug
Singapore, 18 December, 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome (MDS). The drug, known as rigosertib, is currently in a Phase 3 clinical trial to assess the efficacy and
August 5, 2019
Collaborate: We Work Closely with Global Business Partners
Collaborate: We work closely with our global business partners and take care of their products as if they were our own. We also manage complex regulatory landscapes in our regions. Here’s Ulrich Kosciessa from photonamic GmbH discussing our successful partnership. Click on the image above to view.
August 1, 2018
10 Years of Partnering
ST began with a single drug and a single global partner in 2008. Today, our company collaborates with several high-class biotechnology and pharma partners around the globe. All have been prudently selected because their products fulfill an unmet medical need. In 10 years, ST has executed a strategy of identifying promising mid-to-late-stage compounds for
July 30, 2018
CEO Carlo Montagner Discusses Recent Partnership Deal
This article appeared on page 36 in Pharma Asset Insights (a Scrip industry publication). Click on the Fullscreen button in the middle of the magazine below to read it or scroll down to read the article within this webpage. “Our most recent partnership deal was with US-based Puma Biotechnology (NASDAQ: PBYI). This
March 19, 2016
From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win
SARAH-JANE TASKER | THE AUSTRALIAN| MARCH 19, 2016 12:00AM From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win Bozena Zembrzuski and Carlo Montagner reflect on their decision to found Specialised Therapeutics and bring Abraxane to Australia. Picture: Aaron Francis After years working for big pharma in the US,